For years the planet's premier poisoner,
Monsanto, ego driven and
destroyed by debt, tried to peddle itself off to stronger firms with
sane, profitable management. American Home Products asked for
Monsanto's hand in marriage, but when announcements went out
activists worldwide emailed them with warnings: You're marrying the
Next week AHP declared they needed to know more about their partner
before they danced, and dropped the acquisition. Finally a deal was
struck with Pharmacia Upjohn, but first Monsanto had to sell G. D.
Searle and its NutraSweet/Equal business to eliminate the liability
baggage. At least Monsanto could hide its losses in the balance
sheet of a larger, profitable international company.
The honeymoon must have been a disaster, for now PU's Monsanto
operation is being spun off to stockholders as separate shares. Call
it a divorce! Shareholders will receive shares of isolated Monsanto
plus shares in Pfizer, the international giant which is acquiring PU
for 60 Billion.
Poor Monsanto is alone again, a tired divorcee with no place to hide
its losses. So the words of Mohammad Ali are fulfilled: THEY CAN
RUN, BUT THEY CAN'T HIDE.
To which we add the immortal admonition of
another great black athlete, baseball's Satchel Paige:
Never look back, something might be gaining on you!
PS: It's us!
Read on for the news release below. Remember while all this is going
on, Neotame, a more potent aspartame (NutraSweet/Equal/Spoonful, Canderel)
has been approved. FDA would not approve it for years so Monsanto
sold the rights to Child's in Boston.
FDA knows Aspartame Disease
has been declared a global plague and there is a new medical text,
Aspartame Disease: An Ignored Epidemic.
This act by the FDA after being saturated by complaints from
consumers for 20 years on aspartame goes down in the history books
as showing that the FDA has absolutely no concern at all for
consumer health or safe food and drugs, but as Ed Horton, Editor of
the prestigious Lancet wrote in May a year ago:
"FDA takes money
from industry and endangers the lives of the people."
approved it should be immediately removed. Information will be put
on www.dorway.com on how to object and ask for a hearing.
in this country needs to get involved. Aspartame Disease may end up
being one of the largest plagues in world history. It's synergistic
effect with Neotame is just continued mass poisoning of the public.
I have just returned from speaking with representatives of the
European Union, and asking for the ban of aspartame.
Petition has also been filed with the FDA who has disregarded every
effort for 20 years showing not only have they committed the heinous
crime of approving a deadly chemical poison for human consumption
but saturated with complaints, and after three congressional
hearings they want to poison the public even more.
Mission Possible International
9270 River Club Parkway
Duluth, Georgia 30097
New York Times
Date: Mon, 15 Jul 2002
To: (Recipient list suppressed)
From: "John T. Linnell" <firstname.lastname@example.org>
Subject: Monsanto getting yet another new owner
New York Times
15 July 2002
Pfizer Said to Buy Large Drug Rival in $60 Billion Deal
By ANDREW ROSS SORKIN
The drug giant Pfizer Inc. has agreed to acquire the
Corporation for $60 billion in stock, making it by far the most
dominant drug maker in the world, according to executives close to
The transaction, which was approved yesterday by the boards of both
companies and is expected to be announced today, these executives
said, would be the largest of the many recent mergers in what
remains a troubled and fragmented industry.
Drug companies, under intense pressure from politicians, employers
and managed care companies to limit price increases, are having a
hard time finding breakthrough products that would assure the robust
earnings growth investors demand. Pfizer's acquisition of Pharmacia,
resulting in a company that would still control only 11 percent of
the global market, is likely to hasten the industry's continued
The merger would create a behemoth with $48 billion in projected
sales and many of the nation's most widely used drugs.
Pfizer "which already owns
Zoloft, the antidepressant; Lipitor, the nation's
most widely prescribed cholesterol-lowering drug; and Viagra" would
also gain control of Pharmacia's Celebrex and Bextra, two
high-selling arthritis drugs, and Detrol, a drug that treats bladder
Pharmacia, formerly Pharmacia & Upjohn, is also the maker of the
Nicorette gum smokers use to help them quit, the Rogaine baldness
treatment and Luden's throat drops.
Executives close to the deal said that by creating economies of
scale, the merger would help Pfizer to limit price increases. Pfizer
is already being conservative about raising its prices, they say,
noting that it has increased its price for Lipitor only modestly
since acquiring it in the 2000 acquisition of Warner-Lambert.
Pfizer's headquarters would remain in Midtown Manhattan. Pharmacia
is based in Peapack, N.J. It is unclear how many of the combined
company's 150,000 employees would be let go.
Pharmacia recently completed the purchase of AT&T's former
headquarters in Basking Ridge, N.J. It is unclear what would happen
to its plans to relocate 2,500 employees there.
The Pharmacia acquisition would lengthen Pfizer's lead as the
largest drug maker in the United States and would vault it to the
top spot in Europe, Japan and Latin America.
Pfizer's proposed acquisition requires approval by regulators in
both the United States and Europe. Pfizer currently has about 8
percent of the global market, while GlaxoSmith-Kline, the
second-largest drug company, controls 7.3 percent.
Analysts and investors have long speculated that many pharmaceutical
companies would be engulfed in a rash of mergers, leaving only a
handful of gigantic survivors. But so far, the largest expected
mergers have not materialized, analysts said, because the companies
and investors have questioned the long-term benefits.
Pfizer's deal could pressure rivals like
GlaxoSmithKline, which has
been struggling to discover enough new drugs to make up for those
now losing their patent protection, to make acquisitions simply to
GlaxoSmithKline's chief financial officer,
John Coombe, said last
month that his company had been eyeing Bristol-Myers Squibb, itself
plagued by problems.
Pfizer's proposed acquisition of Pharmacia would help sustain its
growth, the executives contend, because 11 of its 12 combined
blockbuster drugs will be protected by patents through 2010. Its
pipeline of drugs in late stages of development would be expanded
with several promising Pharmacia drugs, including eplerenone, a new
category of treatment for cardiovascular diseases; parecaxib, an
injectable arthritis treatment; and CDP-870, another drug that treats
With an enlarged research and development budget, Pfizer hopes to
discover and develop more new drugs faster than its competitors. The
combination would have nearly 120 new chemical entities in
development and 80 so-called drug enhancement projects.
The deal would also introduce Pfizer to two markets it has never
been in before: cancer treatment and ophthalmology.
Analysts have questioned the value of the drugs
Pharmacia has in
"Although the company's pipeline contains a number of
interesting new products," Peter Norman, a pharmaceutical consultant
and analyst, wrote in a recent report, "none have clear blockbuster
A swirl of controversy surrounds one and possibly two of Pharmacia's
top selling arthritis drugs, Celebrex and Bextra. Last month,
Express Scripts, one of the largest pharmacy benefit-management
companies, said that Celebrex and a rival Merck drug, Vioxx, were
being overly prescribed and have only a narrow benefit over older
drugs like ibuprofen and naproxen, which are available in generic
and over-the-counter versions for a fraction of the price.
Express Scripts said it was recommending that its clients, which
include many employer health plans, require patients who are not at
risk of ulcers to try generic pain relievers first, possibly denting
sales of Celebrex and Bextra, which is similar.
Washington lawmakers have been vocal in recent months about rising
drug prices and their cost to uninsured senior citizens and states
that have to pay escalating Medicaid bills.
But the deal will probably be approved by regulators because the
companies have few overlapping drugs. The only possible overlap may
be between Pharmacia's Detrol and a competing drug that Pfizer is
currently developing. Executives close to the transaction expect the
deal to be completed by the end of the current year.
The executives said they expected the deal to create as much as $2.5
billion in annual savings by 2005. They expect savings of $1.4
billion in 2003 and $2.2 billion in 2004. The savings will come from
cuts in administrative costs, purchasing, manufacturing,
distribution and research and development.
Pfizer's absorption of Warner-Lambert was widely admired as a model
of how to fully exploit an acquired portfolio of blockbuster drugs.
Pfizer's chairman and chief executive, Henry A. McKinnell, who
conceived of the deal, would run the combined company. Fred Hassan,
Pharmacia's chairman and chief executive, would become vice chairman
of Pfizer and get a seat on the board.
Under the deal, Pfizer would trade 1.4 of its shares for each share
of Pharmacia, according to the executives. That price of $45.08 a
share, based on Friday's close, represents a 38 percent premium over
Pharmacia's stock price of $32.59. Pfizer shareholders would own 77
percent of the combined company, the executive said, while
Pharmacia's shareholders would own 23 percent.
Prior to the completion of the deal,
Pharmacia plans to proceed with
its previously announced spinoff to its shareholders of its
remaining stake in Monsanto, the executives said. As a result of the
spinoff, Pharmacia's shareholders would actually receive the
equivalent of about a 44 percent premium, they said.
Pfizer also plans to announce today that it will expand its $10
billion stock repurchase to $16 billion, a measure that may help
stabilize the value of its stock. After most merger announcements,
the acquirer's stock at least temporarily declines.
Pfizer was advised by
Lazard and Bear, Stearns & Company and
represented by the Cadwalader, Wickersham & Taft law firm.
Pharmacia was advised by Goldman, Sachs and represented by the
Sullivan & Cromwell law firm.